

# Umecrine Cognition attends the 43rd Annual JP Morgan Healthcare Conference

**STOCKHOLM – January 13, 2024.** Umecrine Cognition today announced that the company will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, USA, on January 13–16, 2025. The annual meeting is a premier event uniting global life science and healthcare leaders, innovators, and investors.

Umecrine Cognition is developing a new class of drugs that targets chronic neuroinflammation, a pathological process that induces debilitating symptoms, e.g., cognitive impairment and severe fatigue, in numerous medical conditions, including primary biliary cholangitis (PBC) and Parkinson's disease. The company's CEO, Anders Karlsson, and SVP/CSO, Magnus Doverskog, will attend the annual JP Morgan Healthcare Conference in San Francisco.

The company is currently evaluating the therapeutic effect of its most advanced drug candidate golexanolone in a clinical Phase 1b/2 study in PBC. In November 2024, the company presented positive interim results at the AASLD Liver Meeting in San Diego from the initial phase of the trial showing that golexanolone was well-tolerated by patients (n=8), achieved clinically relevant drug exposure levels, and did not require dose adjustments. The company is currently conducting the second phase of the study and is expected to report further data during first half of 2025.

"Current treatments for primary biliary cholangitis are effective in managing disease progression. However, these drugs lack a therapeutic effect on cognitive symptoms and pathological fatigue. Our most advanced drug candidate, golexanolone, has the potential to address these clear unmet medical needs. The recent interim results from our ongoing clinical study of golexanolone have sparked great interest from healthcare professionals, clinical investigators, and global life science actors. We look forward to continuing ongoing dialogues and initiating new contacts with potential partners at the upcoming annual JP Morgan conference in January," comments Anders Karlsson, CEO of Umecrine Cognition.

## Contact

Anders Karlsson, CEO, Umecrine Cognition AB Phone: +46 70 918 00 10  
E-mail: anders.karlsson@umecrine.se

## Attachments

---

[Umecrine Cognition attends the 43rd Annual JP Morgan Healthcare Conference](#)